Search Within

Martin Henner Voss

  1. "2014"
Formats
  1. Meeting Abstract (14)
  2. Journal Article (3)
Groups
  1. Department of Medicine (17)
  2. Genitourinary Oncology Service (17)
  3. Solid Tumor Oncology Division (17)
  4. Epidemiology and Biostatistics (4)
  5. Human Oncology and Pathogenesis Program (4)
  6. Surgery (4)

More Groups

People
  1. Robert Motzer (8)
  2. James Hsieh (6)
  3. Abraham Hakimi (3)
  4. Paul Russo (3)
  5. Victor Reuter (3)
  6. Ana Maria Molina (2)

More People

Years
  1. 2014 (17)
Publications
  1. Journal of Clinical Oncology (9)
  2. BJU International (4)
  3. Annals of Oncology (2)
  4. American Journal of Surgical Pathology (1)
  5. Clinical Cancer Research (1)
Publishers
  1. American Society of Clinical Oncology (9)
  2. Wiley Blackwell (4)
  3. Oxford University Press (2)
  4. American Association for Cancer Research (1)
  5. Lippincott Williams & Wilkins (1)

Results (17)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Identification and validation of predictive biomarkers (BM) for everolimus (EVE) in metastatic renal cell carcinoma: Analysis of 442 patients on RECORD-3
    Meeting Abstract

    Voss, M. H.; Chen, D.; Marker, M.; Hamilton, M.; Kalfoglou, C.; Hsieh, J.; Knox, J. J.; Anak, O.; Motzer, R. J.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • First-in-human phase I "basket" study of Debio1347 (CH5183284), a novel FGFR inhibitor, in patients FGFR genoinically activated advanced solid tumors
    Meeting Abstract

    Voss, M. H.; Adamo, B.; Heist, R. S.; Gandhi, L.; Moulon, C.; Tanaka, H.; Ishii, N.; Vasiln, A.; Aoki, Y.; Nicolas-Metral, V.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • A phase I/II study to assess the safety and efficacy of pazopanib and MK-3475 in subjects with advanced renal cell carcinoma
    Meeting Abstract

    McDermott, D. F.; Infante, J. R.; Voss, M. H.; Motzer, R. J.; Haanen, J. B. A. G.; Chowdhury, S.; Perini, R. F.; Iannone, R.; Hodge, R.; Figueroa, D.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Hammers, H. J.; Plimack, E. R.; Infante, J. R.; Ernstoff, M. S.; Rini, B. I.; McDermott, D. F.; Razak, A. R. A.; Pal, S. K.; Voss, M. H.; Sharma, P.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • A two-part phase 2 randomized study of dalantercept and axitinib versus placebo plus axitinib in advanced renal cell carcinoma: Results from the part 1 dose escalation cohorts
    Meeting Abstract

    Atkins, M. B.; Voss, M. H.; Plimack, E. R.; Rini, B. I.; Alter, R.; Dawson, N. A.; Beck, J. T.; Bhatt, R. S.; Pappas, K. M.; Wilson, D.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Amin, A.; Plimack, E. R.; Infante, J. R.; Ernstoff, M. S.; Rini, B. I.; McDermott, D. F.; Knox, J. J.; Pal, S. K.; Voss, M. H.; Sharma, P.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (MRCC)
    Meeting Abstract

    Hammers, H.; Plimack, E. R.; Infante, J. R.; Ernstoff, M.; Rini, B. I.; McDermott, D. F.; Razak, A.; Pal, S. K.; Voss, M.; Sharma, P.; more...
    Annals of Oncology (2014)

    Fulltext@MSK | Save
  • DART Study: A phase 2 randomized trial of dalantercept plus axitinib versus placebo plus axitinib in advanced renal cell carcinoma (RCC): Results from the part 1 dose escalation cohorts
    Meeting Abstract

    Voss, M. H.; Plimack, E.; Rini, B.; Atkins, M. B.; Alter, R.; Beck, J. T.; Bhatt, R. S.; Pappas, K.; Wilson, D.; Sherman, M. L.; more...
    BJU International (2014)

    Fulltext@MSK | Save
  • A composite score of 5 circulating biomarkers predicts benefit from everolimus: Results from 442 patients (pts) randomized on RECORD-3
    Meeting Abstract

    Voss, M. H.; Chen, D.; Marker, M.; Hsieh, J.; Knox, J. J.; Anak, O.; Motzer, R. J.
    BJU International (2014)

    Fulltext@MSK | Save
  • Phase I study of nivolumab in combination with ipilimumab (IPI) in metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Hammers, H.; Plimack, E. R.; Infante, J. R.; Ernstoff, M. S.; Rini, B.; McDermott, D. F.; Razak, A.; Pal, S. K.; Voss, M. H.; Sharma, P.; more...
    BJU International (2014)

    Fulltext@MSK | Save